Angion Biomedica Corp. Has Signed Licensing Option With Memorial Sloan Kettering Cancer Center For Novel Vaccine Platform.

NEW YORK -- Angion Biomedica Corp. has signed an exclusive world-wide licensing option with Memorial Sloan Kettering Cancer Center in New York City (MSKCC) for a novel vaccine platform developed by Professor Samuel Danishefsky. Professor Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the Sloan-Kettering Institute and the Centennial Professor of Chemistry at Columbia University.

This novel vaccine platform enables presentation of multiple carbohydrate antigens on a single synthetic scaffold and has been shown to trigger an in vivo immune response to multiple oncology related targets. The vaccine scaffold can be customized for various clinical indications and represents a major advance for immunotherapy.

A Phase I clinical trial is scheduled to start early in 2009.

About Angion Biomedica Corp.:

Angion Biomedica Corp. is a privately held biopharmaceutical company focused on discovering and developing novel targeted therapeutics for patients with severe and unmet medical conditions. Angion has a diverse clinical and preclinical stage product pipeline addressing acute organ injury, fibrosis and cancer. Angion partners include leading biopharmaceutical companies and academic centers. Angion's first-in-class HGF mimetic is in clinical development; a Phase I clinical trial in healthy volunteers and a Phase IIa clinical trial in patients have been successfully completed.

For additional information, please visit www.angion.com.